Alcidian Secures $23 Million Deal with University Hospitals Sussex for Miya Precision EPR Platform
Alcidian Group announced a 7‑year contract worth about A$35 million ($23 million) with University Hospitals Sussex to implement its Miya Precision electronic patient record (EPR) platform. The agreement will generate roughly A$8.5 million ($5.6 million) in revenue for Alcidian in fiscal 2026, expanding the firm’s footprint in the UK’s integrated care system.
Clinical Trial Endpoint by Counting Hairs - Story of Clinical Trials in Androgenetic Alopecia (Hair Loss)
Veradermics announced that its extended‑release oral minoxidil (VDPHL01) met primary endpoints in a pivotal Phase 2/3 trial of 519 men with androgenetic alopecia. The study showed a mean increase of 30.3 hairs/cm² (once‑daily) and 33.0 hairs/cm² (twice‑daily) in non‑vellus target‑area hair...
Caliway Secures FDA Clearance for CBL-514 Clinical Trial
Caliway Biopharmaceuticals received FDA clearance for its CBL‑0302 IND application, clearing the path for a pivotal global Phase III trial of CBL‑514 aimed at reducing abdominal subcutaneous fat. The double‑blind, placebo‑controlled study will enroll roughly 320 participants in the United States, Canada...
Late-Breakers to Look Out for at ASCO 2026
ASCO 2026’s late‑breaker session will unveil a slate of pivotal trials that could reshape treatment algorithms across liver, bladder, pancreatic, prostate, multiple myeloma and several rare cancers. AstraZeneca will present EMERALD‑3 and POTOMAC data, pushing its Imfinzi‑based combos into first‑line...
Money, Patience, Intent—And Animal Models Drive Drug Discovery
After we showed that we can discover a drug in the UAE from scratch, many countries and their R&D organizations started reaching out with the offers "set up a site in our country and gain access to our wonderful population...
Oral Wegovy Backed by CHMP at May Meeting
The European Medicines Agency’s CHMP gave a positive opinion on Novo Nordisk’s oral formulation of Wegovy, marking the first EU approval for an oral GLP‑1 weight‑loss drug. The endorsement paves the way for a launch in select non‑US markets in...
EU Opens Public Consultation on Biotech Act II, Targeting Industrial Fermentation and Biomanufacturing
The European Commission opened a public consultation on a proposed Biotech Act II, extending the EU’s biotech framework to cover industrial fermentation, cultivated biomass, and precision‑fermentation products. Stakeholders from alternative‑protein and industrial‑biotech firms submitted feedback urging clearer labeling, safety assessments, and...
FEATURE: From Lab Idea to $2.25 Billion: Ultrasound Destroys Cancer without Scalpels
Biomedical engineer Zhen Xu’s 25‑year effort produced histotripsy, an ultrasound‑based method that liquefies tumor cells without incisions. Her start‑up HistoSonics, founded in 2009, was valued at $2.25 billion after a majority‑stake investment. The technique earned FDA approval for liver cancer in...
Regeneron’s Melanoma Immunotherapy Misses Primary Endpoint, Shares Plunge
Regeneron Pharmaceuticals announced that its late‑stage melanoma trial combining the antibody fianlimab with PD‑1 inhibitor cemiplimab failed to meet its primary endpoint, prompting a double‑digit intraday share decline and prompting law‑firm investigations into prior disclosures. The setback raises questions about...
DNA Methylation Variability May Improve Precision Cancer Treatment Strategies
A new review in Genes & Diseases highlights DNA methylation heterogeneity as a driver of tumor microenvironment complexity. It distinguishes intra‑tumor and inter‑patient methylation variability and links these patterns to tumor evolution, immune escape, and metabolic reprogramming. Advances in quantitative...
Junshi Biosciences Wins China NMPA Approval for Loqtorzi HER2‑Urothelial Cancer Combo
Junshi Biosciences announced that China’s National Medical Products Administration has approved Loqtorzi, a toripalimab‑disitamab vedotin combo, for first‑line treatment of HER2‑expressing advanced urothelial carcinoma. The Phase III trial showed median progression‑free survival of 13.1 months and overall survival of 31.5 months, far outpacing...
Low-Dose Ketamine Shows Promise for Easing Chronic Fatigue
NIH researchers ran a randomized, double‑blind crossover trial with ten adults experiencing chronic fatigue from cancer, fibromyalgia, lupus and ME/CFS. A single low‑dose ketamine infusion lowered fatigue scores by 21% on day three, meeting the study’s 20% benchmark, while the...
Stem‑Cell Transplants Restore Insulin Production in Type 1 Diabetes, Early Trial Shows
Researchers reported that stem‑cell‑derived beta cell transplants restored measurable insulin production in a small cohort of Type 1 diabetes patients. The early results demonstrate that lab‑grown cells can survive, mature and function after implantation, offering a potential regenerative route for a...
Asundexian Cuts Recurrent Stroke Risk 26% Without Raising Bleeding in Global Phase 3 Trial
In the OCEANIC-STROKE Phase 3 trial, asundexian lowered recurrent stroke risk by 26% without elevating major bleeding rates, a result that could reshape secondary stroke prevention. The study enrolled 12,327 patients across 37 countries, comparing daily 50 mg asundexian to placebo...
NYU Langone mRNA Vaccine Cuts Melanoma Recurrence Risk by 49% in 5‑Year Study
NYU Langone Health’s Perlmutter Cancer Center reported that the personalized mRNA vaccine intismeran, when combined with pembrolizumab, lowered the five‑year risk of melanoma recurrence or death by 49% compared with pembrolizumab alone. The data, presented at ASCO and published in...
UBS Lifts Jazz Pharma Price Target to $307, Upgrades to Buy
UBS analyst Ashwani Verma upgraded Jazz Pharmaceuticals (JAZZ) to Buy on May 19, raising the price target from $188 to $307 – a 63% jump that eclipses the prior consensus of $242. The move comes ahead of the August 25...
FDA Approves Datroway, First TROP2‑ADC for First‑Line Metastatic Triple‑Negative Breast Cancer
The U.S. FDA has approved Datroway (datopotamab deruxtecan‑dlnk), the first TROP2‑directed antibody‑drug conjugate for first‑line treatment of metastatic triple‑negative breast cancer in patients ineligible for PD‑1/PD‑L1 inhibitors. The approval follows a Phase 3 trial that demonstrated a median overall‑survival improvement of...
Kura Oncology’s SWOT Analysis: Biotech Stock Faces Launch Test
Kura Oncology secured FDA approval in November 2025 for Komzifti (ziftomenib) to treat relapsed or refractory NPM1‑mutated acute myeloid leukemia, propelling its stock nearly 100% higher over the past year. However, Q4 2025 sales fell short of analyst expectations, highlighting early‑launch...
Bispecifics in the Community: Infrastructure, Education, the Future
Bispecific antibodies are becoming a pivotal oncology therapy, delivering durable responses in relapsed or refractory hematologic cancers and moving into earlier treatment lines. Their step‑up dosing schedules and intensive toxicity monitoring demand new workflows, remote therapy monitoring, and robust coordination...
Prosight Management Invests $10.3 M in Nektar Therapeutics Ahead of Phase‑3 ZENITH‑AD Launch
Prosight Management bought 180,367 Nektar Therapeutics shares for an estimated $10.27 million, raising its stake to $52.88 million (8.7% of its assets). The purchase comes as Nektar prepares to launch its Phase‑3 ZENITH‑AD trial for rezpegaldesleukin, a potential treatment for atopic dermatitis...
Viking Therapeutics Emerges as Prime Obesity‑Drug Acquisition Target
Viking Therapeutics is being touted as a leading acquisition candidate after its late‑stage GLGL‑1/GIP obesity drug VK2735 showed 12.2%‑14.7% weight loss in Phase 2 trials and its Phase 3 VANQUISH studies are fully enrolled. With $603 million in cash and a market cap...
Epigenetic Editing Advances Toward Safer Gene Therapies
1/Here is an excellent article by @TheEconomist which sheds light on a new and promising Gene Editing modality called EpiGenetic Editing. Unlike its older and more clinically mature Gene Editing “siblings” - CRISPR, Base Editing, Prime Editing and RNA Editing,...
Cancer Immunotherapy Surge: Emerging Treatments and Future Outlook
I wrote about the remarkable proliferation of cancer immunotherapies, and what's in store https://t.co/od4MeFMGik https://t.co/5jI10LLbLq
Solar Reactor Turns CO₂ and Sunlight Into Bacterial Biomass, Paving Way for Air‑Based Manufacturing
Scientists at Queen Mary University of London have built an integrated solar reactor that uses sunlight, water‑splitting and enzymatic chemistry to convert carbon dioxide into living E. coli biomass. The proof‑of‑concept, published in the Journal of the American Chemical Society, could...
Pharming Group Secures EU Approval for Joenja, First Treatment for Rare Immunodeficiency
Pharming Group announced that the European Commission granted marketing authorisation for Joenja (leniolisib), the first approved therapy for activated PI3K delta syndrome (APDS) in the EU. The approval, covering all 27 EU members plus Norway, Iceland and Liechtenstein, paves the...
KAUST Engineers Six‑protein Nanoscale Factory Inside Living Cells to Make Medicines on Site
Researchers at King Abdullah University of Science and Technology (KAUST) have built a synthetic organelle that carries six enzymes into mammalian cells, where they assemble a nanoscale drug factory that produces violacein, a bioactive compound with therapeutic potential. The breakthrough...
Blood‑Based Age Test Signals Ten‑Fold Dementia Risk in UK Study
Researchers analyzing UK Biobank data found that a metabolite‑derived biological age metric, MileAge delta, is linked to a ten‑fold increase in all‑cause dementia risk for carriers of the APOE gene. The finding could reshape early‑diagnosis strategies and accelerate biotech investment...
Deep Generative Molecular Design and Its Value in Modern Drug Discovery (Paper Feb 26)
The February 2026 review maps the rapid rise of deep generative molecular design in drug discovery, arguing that AI is moving from virtual screening toward the creation of new, testable drug hypotheses. It categorises the field into three technical families—graph‑based...
EMA Gives Positive Opinion on Serplulimab for First‑Line Squamous NSCLC
The European Medicines Agency (EMA) issued a positive opinion on serplulimab, marketed as HETRONIFLY, for use as a first‑line treatment of squamous non‑small cell lung cancer (NSCLC). The endorsement comes from Shanghai Henlius Biotech, the drug’s developer, and signals a...
Merck Gets EU CHMP Nod for KEYTRUDA‑Padcev Combo in Bladder Cancer
Merck announced that the European Medicines Agency’s CHMP has issued a positive recommendation for its KEYTRUDA plus Padcev regimen in resectable muscle‑invasive bladder cancer, sending the stock up 2.57% to $118.85. The endorsement, based on the Phase 3 KEYNOTE‑905 trial conducted...
AI Systems Slash Drug Discovery Time, Yield New Cancer and Neurodegenerative Candidates
FutureHouse’s Robin and DeepMind’s Co‑Scientist AI agents have collapsed drug‑candidate timelines by up to 200‑fold, while NIH’s TRANSLATE‑AI has identified three repurposed drugs for Alzheimer’s and Parkinson’s with 98% pre‑clinical accuracy. The breakthroughs promise faster routes to clinical trials for...
FDA Grants First U.S. Approval for Bulevirtide, Gilead’s Hepatitis D Therapy
The FDA approved Gilead Sciences' bulevirtide‑gmod (Hepcludex) on May 22, 2026, marking the first U.S. therapy for chronic hepatitis delta virus. The drug earned accelerated approval, priority review, breakthrough therapy and orphan‑drug designations after a phase‑3 trial showed a 48%...
Novo Nordisk Cuts Drug Launch Time by Two‑Thirds Using AI, Expands India Hub
Novo Nordisk announced that artificial‑intelligence tools are trimming new‑drug launch cycles by as much as two‑thirds, with its Bengaluru, India centre now handling a majority of preparatory work for global rollouts. The move aims to recapture momentum in the fast‑growing...
AbbVie’s MAVIRET Wins Positive CHMP Opinion, 96% Cure Rate for Acute Hepatitis C
AbbVie announced that the European Medicines Agency’s CHMP has issued a positive opinion on MAVIRET for acute hepatitis C, citing a 96% cure rate in an eight‑week Phase 3 trial. The recommendation paves the way for EU approval in the third...
Deep Phenotyping Reveals Skin Remodeling in Sclerosis Treatment
A recent study employing deep phenotyping—integrating high‑resolution imaging, transcriptomics, and proteomics—has uncovered significant skin remodeling in patients undergoing experimental sclerosis therapy. The data show a 30% reduction in skin thickness and a 45% drop in collagen deposition after six months...
Eli Lilly’s Triple Agonist Retatrutide Hits 28.3% Mean Weight Loss in TRIUMPH-1 Phase 3, Blowing Past Tirzepatide Benchmarks & Rewriting...
Eli Lilly’s triple‑agonist retatrutide delivered a 28.3% mean body‑weight reduction (about 70 lb) after 80 weeks in the phase‑3 TRIUMPH‑1 trial, far surpassing tirzepatide’s ~22.5% peak. The 12 mg dose drove 62.5% of participants to lose at least 25% of their weight, with 27.2%...
Regeneron Reports Positive Phase 1/2 Data for Lynozyfic in Systemic AL Amyloidosis
Regeneron Pharmaceuticals released positive Phase 1/2 LINKER‑AL2 data for Lynozyfic in second‑line-plus systemic AL amyloidosis. The bispecific BCMAxCD3 antibody, built on VelociImmune technology, could become the first approved therapy after standard‑of‑care failure, a gap affecting thousands of patients.
Scribe Therapeutics Unveils Safer CRISPR Platform Targeting Heart Disease
Scribe Therapeutics announced at the ASGCT 2026 meeting that its new ELXR CRISPR platform silences the PCSK9 gene with 10‑ to 100‑fold fewer off‑target edits and achieved an 18‑month cholesterol‑lowering effect in non‑human primates, positioning the company for first‑in‑human trials...
EU Approves Agios' PYRUKYND as First Disease‑Modifying Therapy for Adult Thalassemia
Agios Pharmaceuticals announced that the European Commission has granted approval for PYRUKYND (mitapivat) to treat adult patients with alpha‑ or beta‑thalassemia. The authorization covers all EU member states and marks the first disease‑modifying therapy available for both transfusion‑dependent and non‑transfusion‑dependent...
Ionis Pharmaceuticals’ SWOT Analysis: Stock Gains Momentum on FDA Approval
Ionis Pharmaceuticals (NASDAQ:IONS) secured FDA approval for REDEMPLO, the first siRNA therapy targeting familial chylomicronemia syndrome (FCS), in November 2025. The drug’s clean label, quarterly at‑home dosing and broad indication have positioned it for rapid uptake, with payer agreements covering...
Lilly's Retatrutide Cuts 30% Body Weight, New GLP‑1 Studies Target Plateaus and Joint Inflammation
Lilly’s investigational triple‑agonist retatrutide delivered an average 30.3% weight loss after 104 weeks in a Phase 3 trial, matching bariatric‑surgery outcomes. At the same time, researchers uncovered cellular mechanisms that cause GLP‑1 weight‑loss plateaus and detected GLP‑1 hormone in arthritic joint...
EMA Starts Review of Regeneron's Otarmeni Gene Therapy for Genetic Hearing Loss
Regeneron Pharmaceuticals announced that the European Medicines Agency has accepted the Market Authorization Application for Otarmeni, its AAV‑based gene therapy targeting biallelic OTOF‑variant hearing loss. The acceptance moves the product into a formal EMA review, the first step toward potential...
Novo Nordisk's Oral Wegovy Pill Gets EU Approval Recommendation
Novo Nordisk announced that the European Medicines Agency’s CHMP has recommended marketing authorisation for its oral Wegovy pill, a semaglutide formulation that achieved a 16.6% average weight loss in trials. The recommendation paves the way for a European launch in...
FDA Clears AstraZeneca‑Daiichi Sankyo’s Datroway for Metastatic Triple‑Negative Breast Cancer
AstraZeneca and Daiichi Sankyo announced FDA approval of Datroway for adult patients with unresectable or metastatic triple‑negative breast cancer. The decision follows a Phase 3 trial that showed a 5‑month median overall‑survival gain, positioning the drug as a Category 1 preferred first‑line...
Final Frontier for Meds? UK Startup Sends Drug-Making Into Space
BioOrbit, a UK biotech, launched its Box‑E microgravity crystallisation unit to the International Space Station on a SpaceX flight, aiming to produce ultra‑pure protein crystals for self‑injected cancer drugs. The six‑week orbital test leverages weightlessness to create stable crystal structures...
Venus Remedies Gets Saudi FDA Approval for Speciality Oncology Therapy
Venus Remedies Limited announced that the Saudi Food and Drug Authority has granted marketing authorisation for its specialty oncology drug Plerixafor, a stem‑cell mobiliser used in autologous transplants. This marks the first global approval for the therapy, positioning Saudi Arabia...
After Early Semaglutide Lead, Torrent Pharma Eyes US Liver Drug Resmetirom for India Launch
Torrent Pharmaceuticals is conducting a Phase 3 trial of Resmetirom, the first US‑approved drug for metabolic dysfunction‑associated steatohepatitis (MASH), with plans to launch in India once patent barriers lift. The company already commands a strong position in the Indian semaglutide market,...
Pim1 Identified as Promising Therapeutic Target for Inflammatory Arthritis Treatment
Researchers have pinpointed the serine/threonine kinase Pim1 as a pivotal driver of abnormal Th17 cell differentiation in inflammatory arthritis. Elevated Pim1 levels were detected in CD4⁺ T cells from rheumatoid arthritis and ankylosing spondylitis patients, and mice lacking Pim1 in...
Gene-Based Therapies Could Transform Future Pancreatitis Treatment
Pancreatitis remains a largely untreatable inflammatory disease, with current care limited to symptom management. Gene‑based therapies—spanning augmentation, inhibition, and editing—are emerging to address the genetic drivers across lipid‑metabolism, trypsin regulation, ductal secretion, and ER‑stress pathways. Recent preclinical work shows AAV‑mediated...
Pharvaris to File FDA NDA for Oral Deucrictibant, First-in-Class HAE Therapy
Pharvaris announced it will submit an FDA New Drug Application for its immediate‑release oral deucrictibant by the end of June. The filing is backed by Phase 3 RAPIDe‑3 data showing symptom relief in a mean of 1.3 hours, far faster than the...